<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50456">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02135029</url>
  </required_header>
  <id_info>
    <org_study_id>B1481030</org_study_id>
    <secondary_id>STATIN INTOLERANT</secondary_id>
    <nct_id>NCT02135029</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of RN316 (PF-04950615) in Subjects Who Are Intolerant to Statins</brief_title>
  <acronym>SPIRE-SI</acronym>
  <official_title>A Phase 3, Double-blind, Randomized, Placebo and Active Controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia Who Are Intolerant to Statin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, double blinded, active and placebo controlled randomized
      clinical trial to demonstrate a superior lipid lowering effect of RN316 (PF-04950615)
      compared to placebo in subjects who are statin intolerant.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage change from baseline in fasting LDL-C at week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lipid Parameters at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in fasting Total Cholesterol (TC), Apolipoprotein B (Apo B), non HDL-C, Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lipid Parameters at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in fasting Total Cholesterol (TC), LDL-C, Apolipoprotein B (Apo B), non HDL-C, Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lipid Parameters at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute change in fasting LDL-C, TC, HDL-C, non-HDL-C, TG, ApoB, ApoA-I, ApoA-II, and Lp(a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lipid Parameters at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute change in fasting LDL-C, TC, HDL-C, non-HDL-C, TG, ApoB, ApoA-I, ApoA-II, and Lp(a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-04950615 concentration at week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PF-04950615 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-04950615 concentration at week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PF-04950615 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>incidence and titer of anti-drug and neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects discontinuing treatment due to musculoskeletal adverse events</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects discontinuing treatment due to musculoskeletal adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>PF-04950615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>150 mg every 2 weeks by subcutaneous injection for 24 weeks</description>
    <arm_group_label>PF-04950615</arm_group_label>
    <other_name>RN316</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin PO QD</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-04950615</intervention_name>
    <description>150 mg every 2 weeks by subcutaneous injection for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for atorvastatin</intervention_name>
    <description>PO QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperlipidemia

          -  Statin Intolerant

          -  Fasting LDL-C &gt; + 70 mg/dL Fasting TG &lt; = 400 mg/dL

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Cardiovascular or cerebrovascular event or procedure within 90 days

          -  Severe or life-threatening adverse events with past use of statins

          -  Poorly controlled hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481030&amp;StudyName=Randomized%20Clinical%20Trial%20of%20RN316%20%28PF-04950615%29%20in%20Subjects%20who%20are%20Intolerant%20to%20Statins</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>statin intolerance</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
